News for PDS Biotechnology Corporation (PDSB)

PDS Biotechnology (PDSB) to host a virtual Key Opinion Leader event on June 17, 2025, focusing on HPV16-positive head and neck squamous cell carcinoma (HNS

PDS Biotechnology Corporation (NASDAQ:PDSB) unveiled compelling new data on its Versamune HPV (PDS0101) immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ETCompany ParticipantsFrank Bedu-Addo - CEOLars Boesgaard...

VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting

PDS Biotech (PDSB) initiates VERSATILE-003 Phase 3 trial for Versamune® HPV in HPV16-positive head and neck cancer. Reported first-quarter 2025 net los

**media[620801]**

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( PDSB) (”œPDS Biotech” or the ”œCompany”), a late-stage immunotherapy c

PDS Biotechnology (PDSB) announces three clinical trial presentations at the 2025 ASCO Annual Meeting. Key focus on Versamune® HPV (PDS0101) for HPV-re

**media[603423]**

\nUpdate on American Association for Cancer Research Annual Meeting 2025 presentation\n\nPRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Co

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ETCompany ParticipantsTom Johnson - LifeSci...

Updated time slot of 11:00 AM CT on Friday, March 28, 2025 PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( PDSB) (”œPDS

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts.

PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( PDSB) (”œPDS Biotech” or the ”œCompany”), a late-stage immunotherapy

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced t...

PDS Biotechnology received U.S. FDA clearance for its Investigational New Drug application to treat metastatic colorectal carcinoma. Read more here.

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets M

PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( PDSB) (”œPDS Biotech” or the ”œCompany”), a late-stage immunotherapy

**media[560192]**